glp 1 agonist and depression GLP-1s: Are We Ignoring the Psychiatric Risks? An analysis on the role
Description
Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes
Grey literature, conference abstracts, and non-peer-reviewed sources were excluded
1 giugno 2021 [citato 5 giugno 2024];38(6):282139
Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes
